TickerFacts.

Caris Life Sciences, Inc. (CAI): Operating Cash Flow

Annual figures by period end, from SEC filings.

$83.16M
Year ended 2025-12-31
$168.56M
Trailing 12 months to 2026-06-30
2023-12-31: -$276.10M2024-12-31: -$245.20M2025-12-31: $83.16M$83.16M
2023-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31$83.16Mn/m2026-03-03, From 2025-01-01
2024-12-31-$245.20Mn/m2026-03-03, From 2024-01-01
2023-12-31-$276.10Mn/a2026-03-03, From 2023-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Caris Life Sciences, Inc. (CAI)2025-12-31$83.16Mn/m
Guardant Health, Inc. (GH)2025-12-31-$184.76Mn/m
Veracyte, Inc. (VCYT)2025-12-31$136.31M+81.5%
CareDx, Inc. (CDNA)2025-12-31$42.03M+10.5%
Castle Biosciences Inc (CSTL)2025-12-31$64.35M-0.8%
RadNet, Inc. (RDNT)2025-12-31$298.82M+28.2%
Fulgent Genetics, Inc. (FLGT)2025-12-31-$101.64Mn/m
BillionToOne, Inc. (BLLN)2025-12-31$24.59Mn/m
Natera, Inc. (NTRA)2025-12-31$215.30M+58.7%

Compare CAI, GH, VCYT, CDNA side by side · Screen every company in Services-Medical Laboratories ↗